AnaptysBio (ANAB) Projected to Post Earnings on Thursday

AnaptysBio (NASDAQ:ANAB) is anticipated to release its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of $0.89 per share for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, March 6, 2026 at 4:00 PM ET.

AnaptysBio Trading Up 2.1%

Shares of NASDAQ:ANAB opened at $55.41 on Wednesday. AnaptysBio has a 12 month low of $13.99 and a 12 month high of $57.74. The company has a market capitalization of $1.53 billion, a price-to-earnings ratio of -19.65 and a beta of 0.35. The firm’s 50-day moving average is $49.18 and its 200 day moving average is $37.28.

AnaptysBio declared that its Board of Directors has initiated a stock buyback plan on Friday, November 21st that allows the company to buyback $100.00 million in shares. This buyback authorization allows the biotechnology company to reacquire up to 9.6% of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s board of directors believes its shares are undervalued.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on ANAB. HC Wainwright reduced their price target on AnaptysBio from $52.00 to $51.00 and set a “buy” rating on the stock in a report on Monday, November 24th. Wells Fargo & Company increased their target price on AnaptysBio from $51.00 to $81.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 5th. UBS Group assumed coverage on shares of AnaptysBio in a research note on Wednesday, January 7th. They set a “buy” rating and a $70.00 target price for the company. Truist Financial upped their price target on shares of AnaptysBio from $20.00 to $36.00 and gave the stock a “hold” rating in a report on Monday, November 10th. Finally, Wall Street Zen lowered shares of AnaptysBio from a “strong-buy” rating to a “buy” rating in a report on Friday, January 23rd. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $66.89.

Insider Transactions at AnaptysBio

In other news, insider Paul F. Lizzul sold 3,650 shares of the stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $44.71, for a total transaction of $163,191.50. Following the transaction, the insider directly owned 42,088 shares in the company, valued at approximately $1,881,754.48. This trade represents a 7.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Daniel Faga sold 14,281 shares of the business’s stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $44.71, for a total transaction of $638,503.51. Following the completion of the transaction, the chief executive officer directly owned 479,344 shares of the company’s stock, valued at $21,431,470.24. This trade represents a 2.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 156,280 shares of company stock worth $7,254,939. Insiders own 33.50% of the company’s stock.

Institutional Investors Weigh In On AnaptysBio

Institutional investors have recently added to or reduced their stakes in the stock. Smartleaf Asset Management LLC raised its holdings in AnaptysBio by 5,864.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 821 shares in the last quarter. Larson Financial Group LLC lifted its position in AnaptysBio by 54.6% during the third quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 473 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in AnaptysBio by 175.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 1,377 shares in the last quarter. Osaic Holdings Inc. grew its holdings in AnaptysBio by 11,630.0% in the second quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 2,326 shares during the last quarter. Finally, Royal Bank of Canada increased its position in shares of AnaptysBio by 987.3% during the fourth quarter. Royal Bank of Canada now owns 1,718 shares of the biotechnology company’s stock worth $83,000 after purchasing an additional 1,560 shares in the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.